Two Million Fold Improvement in Enzyme Performance
s
Press Release Source: Codexis, Inc. On Wednesday August 24, 2011, 8:00 am EDT
REDWOOD CITY, Calif., Aug. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq:CDXS - News) presented important technical progress in its carbon capture program yesterday at the CO2 Capture Technology Meeting being sponsored this week by the U.S. Department of Energy/National Energy Technology Laboratory in Pittsburgh. Codexis, supported by a grant from the DoE's ARPA-E Recovery Act program, is using its patented CodeEvolver™ directed evolution technology to develop processes to reduce carbon dioxide emissions from coal-fired power plants.
The research program is based on development of customized carbonic anhydrase (CA) enzymes that could catalyze carbon capture under industrial conditions. Data showed CA performance has been improved by about two million fold over natural forms of the enzyme. Evolved CA enzymes are functional and stable in relatively inexpensive, energy efficient solvents for 24 hours at temperatures greater than 90 degrees C.
Use of carbon capture solvents with fully developed enzymes is expected to substantially reduce the costs and energy requirements to capture CO2 produced by coal-fired power plants. The data was presented by James Lalonde, Ph.D., Codexis' Vice President of Biochemistry and Engineering Research and Development. Codexis is jointly developing the technology with CO2 Solution, Inc., Quebec, Canada. (TSX-V:CST.v - News)
A 2011 NETL report estimated that coal-fired power plants account for roughly 37% of total U.S. CO2 emissions and that current technology to capture CO2 would reduce power generating capacity by 30%.
In May 2010, Codexis was selected to receive an ARPA-E Recovery Act program grant for up to $4.7 million from the U.S. Department of Energy for development of innovative technology to remove carbon dioxide from coal-fired power plant emissions. The grant was one of 37 research projects which the DoE said "could fundamentally change the way the country uses and produces energy."
Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell, carbon capture and biobased chemicals. Wastewater treatment is a potential future market. For more information, visit www.codexis.com.
This press release contains forward-looking statements relating to Codexis' research in carbon capture technology and the ability of our carbon capture technology to substantially reduce the costs and energy requirements to capture CO2 produced by coal-fired power plants. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q dated August 3, 2011 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Recent CDXS News
- Codexis to Report First Quarter 2024 Financial Results on May 2 • GlobeNewswire Inc. • 04/18/2024 08:05:10 PM
- Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board • GlobeNewswire Inc. • 04/11/2024 11:05:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:33 PM
- Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Biotech Rallied Strongly On Exclusive Licensing Agreement • AllPennyStocks.com • 02/27/2024 05:15:00 PM
- Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche • GlobeNewswire Inc. • 02/26/2024 09:05:42 PM
- Codexis to Participate in TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:05:47 PM
- Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board • GlobeNewswire Inc. • 02/20/2024 01:05:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:01 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:51:41 PM
- Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28 • GlobeNewswire Inc. • 02/14/2024 09:05:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:19:57 PM
- Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones • GlobeNewswire Inc. • 02/13/2024 09:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:06:35 PM
- seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting • GlobeNewswire Inc. • 02/01/2024 09:05:07 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 07:27:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:30:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:24:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:24:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:23:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:23:40 AM
- Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108 • GlobeNewswire Inc. • 12/27/2023 01:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 01:30:30 PM
- Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase • GlobeNewswire Inc. • 12/13/2023 09:06:00 PM
- Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform • GlobeNewswire Inc. • 12/13/2023 09:05:38 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM